Free‐Water Imaging of the Substantia Nigra in GBA Pathogenic Variant Carriers

Pathogenic variants in the glucocerebrosidase gene (GBA) have been identified as the most common genetic risk factor for Parkinson's disease (PD). However, the features of substantia nigra damage in GBA pathogenic variant carriers remain unclear.

[1]  Jun Liu,et al.  Increased Free Water in the Substantia Nigra in Asymptomatic LRRK2 G2019S Mutation Carriers , 2022, Movement disorders : official journal of the Movement Disorder Society.

[2]  T. Raj,et al.  Transcriptome deregulation of peripheral monocytes and whole blood in GBA-related Parkinson’s disease , 2022, Molecular Neurodegeneration.

[3]  F. Agosta,et al.  Neuroimaging in Glucocerebrosidase‐Associated Parkinsonism: A Systematic Review , 2022, Movement disorders : official journal of the Movement Disorder Society.

[4]  Jong Hun Kim,et al.  Genetic factors affecting dopaminergic deterioration during the premotor stage of Parkinson disease , 2021, NPJ Parkinson's disease.

[5]  Myung Jun Lee,et al.  Genetic factors affecting dopaminergic deterioration during the premotor stage of Parkinson disease , 2021, npj Parkinson's Disease.

[6]  Michael D. Gregory,et al.  Comparison of Transcranial Sonography and [18F]‐Fluorodopa PET Imaging in GBA1 Mutation Carriers , 2021, Movement disorders : official journal of the Movement Disorder Society.

[7]  Seong Jae Hwang,et al.  A multi-scanner neuroimaging data harmonization using RAVEL and ComBat , 2021, NeuroImage.

[8]  D. Perani,et al.  Clinical and Dopamine Transporter Imaging Trajectories in a Cohort of Parkinson's Disease Patients with GBA Mutations , 2021, Movement disorders : official journal of the Movement Disorder Society.

[9]  Y. Sohn,et al.  Glucocerebrosidase Mutations and Motor Reserve in Parkinson's Disease. , 2021, Journal of Parkinson's disease.

[10]  M. Filippi,et al.  Longitudinal clinical, cognitive, and neuroanatomical changes over 5 years in GBA-positive Parkinson’s disease patients , 2021, Journal of Neurology.

[11]  M. Zhang,et al.  Increased free water in the substantia nigra in idiopathic REM sleep behaviour disorder. , 2021, Brain : a journal of neurology.

[12]  T. Demiralp,et al.  Functional Connectivity Analysis in Heterozygous Glucocerebrosidase Mutation Carriers. , 2021, Journal of Parkinson's disease.

[13]  L. Forsgren,et al.  Association of GBA Genotype With Motor and Functional Decline in Patients With Newly Diagnosed Parkinson Disease , 2020, Neurology.

[14]  D. Brooks,et al.  Brain Microglial Activation Increased in Glucocerebrosidase (GBA) Mutation Carriers without Parkinson's disease , 2020, Movement disorders : official journal of the Movement Disorder Society.

[15]  M. T. Pellecchia,et al.  GBA‐Related Parkinson's Disease: Dissection of Genotype–Phenotype Correlates in a Large Italian Cohort , 2020, Movement disorders : official journal of the Movement Disorder Society.

[16]  A. Singleton,et al.  Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross‐Sectional Study , 2020, Movement disorders : official journal of the Movement Disorder Society.

[17]  Michael D. Gregory,et al.  Longitudinal Positron Emission Tomography of Dopamine Synthesis in Subjects with GBA1 Mutations , 2020, Annals of neurology.

[18]  Yen F. Tai,et al.  Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study , 2020, The Lancet Neurology.

[19]  D. Vaillancourt,et al.  Diffusion magnetic resonance imaging-derived free water detects neurodegenerative pattern induced by interferon-γ , 2020, Brain Structure and Function.

[20]  Sonja W. Scholz,et al.  Genetic modifiers of risk and age at onset in GBA associated Parkinson's disease and Lewy body dementia. , 2019, Brain : a journal of neurology.

[21]  Sebastian Heinzel,et al.  Update of the MDS research criteria for prodromal Parkinson's disease , 2019, Movement disorders : official journal of the Movement Disorder Society.

[22]  Sonja W. Scholz,et al.  Genetic modifiers of risk and age at onset in GBA associated Parkinson’s disease and Lewy body dementia , 2019, bioRxiv.

[23]  A. Schapira,et al.  Evolution and clustering of prodromal parkinsonian features in GBA1 carriers , 2019, Movement disorders : official journal of the Movement Disorder Society.

[24]  J. Lanciego,et al.  Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine , 2019, Movement disorders : official journal of the Movement Disorder Society.

[25]  Dag Aarsland,et al.  Cognition among individuals along a spectrum of increased risk for Parkinson’s disease , 2018, PloS one.

[26]  Jeffrey M. Hausdorff,et al.  Cerebral Imaging Markers of GBA and LRRK2 Related Parkinson’s Disease and Their First-Degree Unaffected Relatives , 2018, Brain Topography.

[27]  Chunlei Liu,et al.  Longitudinal atlas for normative human brain development and aging over the lifespan using quantitative susceptibility mapping , 2018, NeuroImage.

[28]  D. Aarsland,et al.  Glucocerebrosidase mutations and neuropsychiatric phenotypes in Parkinson's disease and Lewy body dementias: Review and meta‐analyses , 2018, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[29]  Ofer Pasternak,et al.  Progression marker of Parkinson’s disease: a 4-year multi-site imaging study , 2017, Brain : a journal of neurology.

[30]  J. Kordower,et al.  Aging and Parkinson’s Disease: Different Sides of the Same Coin? , 2017, Movement disorders : official journal of the Movement Disorder Society.

[31]  T. Sanderson,et al.  Mitochondrial Quality Control and Disease: Insights into Ischemia-Reperfusion Injury , 2017, Molecular Neurobiology.

[32]  Oury Monchi,et al.  The role of high‐field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward , 2017, Movement disorders : official journal of the Movement Disorder Society.

[33]  Ragini Verma,et al.  Harmonization of multi-site diffusion tensor imaging data , 2017, NeuroImage.

[34]  Nicola Pavese,et al.  Age at onset and Parkinson disease phenotype , 2016, Neurology.

[35]  M. Albert,et al.  GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease , 2016, Movement disorders : official journal of the Movement Disorder Society.

[36]  Tomoko Oeda,et al.  Impact of glucocerebrosidase mutations on motor and nonmotor complications in Parkinson's disease , 2015, Neurobiology of Aging.

[37]  A. Lang,et al.  Parkinson's disease , 2015, The Lancet.

[38]  D. Vaillancourt,et al.  Longitudinal changes in free-water within the substantia nigra of Parkinson's disease. , 2015, Brain : a journal of neurology.

[39]  A. Schapira,et al.  Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort. , 2015, JAMA neurology.

[40]  A Smith,et al.  Genetic overlap between Alzheimer’s disease and Parkinson’s disease at the MAPT locus , 2015, Molecular Psychiatry.

[41]  D. Krainc,et al.  LIMP-2 expression is critical for β-glucocerebrosidase activity and α-synuclein clearance , 2014, Proceedings of the National Academy of Sciences.

[42]  R. Postuma,et al.  Premotor and nonmotor features of Parkinson's disease. , 2014, Current opinion in neurology.

[43]  S. Gygi,et al.  iPSC-derived neurons from GBA1-associated Parkinson’s disease patients show autophagic defects and impaired calcium homeostasis , 2014, Nature Communications.

[44]  A. Schapira,et al.  Glucocerebrosidase mutations and the pathogenesis of Parkinson disease , 2013, Annals of medicine.

[45]  K. Berman,et al.  The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow. , 2012, Brain : a journal of neurology.

[46]  H. Braak,et al.  Lewy pathology and neurodegeneration in premotor Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[47]  E. Benarroch,et al.  Autonomic involvement in Parkinson's disease: Pathology, pathophysiology, clinical features and possible peripheral biomarkers , 2012, Journal of the Neurological Sciences.

[48]  D. Berg,et al.  GBA-associated PD presents with nonmotor characteristics , 2011, Neurology.

[49]  M. Nalls,et al.  Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. , 2009, The New England journal of medicine.

[50]  N. Intrator,et al.  Free water elimination and mapping from diffusion MRI , 2009, Magnetic resonance in medicine.

[51]  T. Vanitallie.  Parkinson disease: primacy of age as a risk factor for mitochondrial dysfunction. , 2008, Metabolism: clinical and experimental.

[52]  Nir Giladi,et al.  Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset , 2008, Neurology.

[53]  Anette Schrag,et al.  Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism , 2006, The Lancet Neurology.

[54]  J. Aharon-Peretz,et al.  Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. , 2004, The New England journal of medicine.

[55]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[56]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[57]  C. Galvagnion.  The Role of Lipids Interacting with α-Synuclein in the Pathogenesis of Parkinson's Disease. , 2017, Journal of Parkinson's disease.